Display options
Share it on

Front Psychol. 2016 Apr 19;7:520. doi: 10.3389/fpsyg.2016.00520. eCollection 2016.

Pharmacological Neuroenhancement in the Field of Economics-Poll Results from an Online Survey.

Frontiers in psychology

Pavel Dietz, Michael Soyka, Andreas G Franke

Affiliations

  1. Department of Physical Activity and Public Health, Institute of Sport Science, University of Graz Graz, Austria.
  2. Private Clinic Meiringen, Clinic for Psychiatry and PsychotherapyMeiringen, Switzerland; Department of Psychiatry and Psychotherapy, Ludwig Maximilian UniversityMunich, Germany.
  3. Department of Social Work and Education, University of Neubrandenburg Neubrandenburg, Germany.

PMID: 27148128 PMCID: PMC4835716 DOI: 10.3389/fpsyg.2016.00520

Abstract

INTRODUCTION: The use of over-the-counter, prescription, and illicit drugs to increase attention, concentration, or memory-often called (pharmacological) neuroenhancement-shows a broad range of prevalence rates among students. However, very little data is available on neuroenhancement among employed persons. The aim of this study was to provide first data on substance use for neuroenhancement among readers of the German "Handelsblatt" coming from the field of economics.

METHODS: Readers of the online edition of the Handelsblatt, a leading print and online medium for the field of economics, were invited to participate in a survey via a link on the journal homepage to complete a web-based questionnaire. Within the questionnaire, participants were asked for their gender, current age, current professional status, hours of work per week, prevalence rates of substance use for the purpose of neuroenhancement as well as for reasons of its use. Binary regression analyses with stepwise forward selection were used to predict the dependent variables "use of illicit and prescription drugs for neuroenhancement" (yes/no), "use of over-the-counter drugs for neuroenhancement" (yes/no), and "use of any drug for neuroenhancement" (yes/no).

RESULTS: A total of 1021 participants completed the anonymous survey. Lifetime prevalence for the use of any drug for neuroenhancement was 88.0% and for the use of illicit and prescription drugs for neuroenhancement 19.0%. Reasons and situations that predicted neuroenhancement with illicit and prescription drugs were "curiosity," "to enhance mood," "for a confident appearance," "stress/pressure to perform," and "deadline pressure."

DISCUSSION: The study shows that neuroenhancement with drugs is a widespread and frequent phenomenon among people belonging to the professional field of economics. Given in the literature that the use of drugs, especially prescription, and illicit drugs, may be associated with side effects, the high epidemic of drug use for neuroenhancement also shown in the present paper underlines the new public health concern of neuroenhancement.

Keywords: addiction; drugs; economy; misuse; neuroenhancement; survey

References

  1. Pharmacotherapy. 2013 Jan;33(1):44-50 - PubMed
  2. BMC Med. 2013 Apr 09;11:102 - PubMed
  3. Ann Surg. 2015 Jun;261(6):1091-5 - PubMed
  4. Int J Drug Policy. 2016 May;31:51-5 - PubMed
  5. Sleep. 2009 Feb;32(2):205-16 - PubMed
  6. PLoS One. 2013 Nov 13;8(11):e77967 - PubMed
  7. Sci Total Environ. 2013 Apr 15;450-451:242-9 - PubMed
  8. EMBO Rep. 2011 Mar;12(3):197-201 - PubMed
  9. Neurosci Biobehav Rev. 2008;32(4):760-76 - PubMed
  10. PLoS One. 2013 Nov 13;8(11):e78702 - PubMed
  11. Addiction. 2005 Jan;100(1):96-106 - PubMed
  12. Pharmacol Res. 2010 Jun;61(6):473-81 - PubMed
  13. PLoS One. 2011;6(11):e28416 - PubMed
  14. Neuropsychopharmacology. 2004 Sep;29(9):1704-14 - PubMed
  15. Pharmacopsychiatry. 2011 Mar;44(2):60-6 - PubMed
  16. J Am Acad Child Adolesc Psychiatry. 2008 Jan;47(1):21-31 - PubMed
  17. J Sleep Res. 2008 Sep;17(3):309-21 - PubMed
  18. Milbank Q. 2004;82(3):483-506, table of contents - PubMed
  19. Ann Clin Psychiatry. 2013 Feb;25(1):27-32 - PubMed
  20. Pharmacopsychiatry. 2011 Nov;44(7):331-8 - PubMed
  21. Postgrad Med. 2015 Apr;127(3):308-22 - PubMed
  22. Am Heart J. 2015 Mar;169(3):426-437.e23 - PubMed
  23. Pharmacopsychiatry. 2015 Nov;48(7):256-64 - PubMed
  24. Aviat Space Environ Med. 2012 Jul;83(7):685-90 - PubMed
  25. Psychiatry Res. 2015 Sep 30;229(1-2):12-20 - PubMed
  26. PLoS One. 2013 Jul 17;8(7):e68821 - PubMed
  27. Virtual Mentor. 2004 Aug 01;6(8):null - PubMed
  28. JAMA. 2002 Aug 21;288(7):835-40 - PubMed
  29. Front Syst Neurosci. 2015 Feb 17;9:10 - PubMed
  30. Eur Arch Psychiatry Clin Neurosci. 2014 Nov;264 Suppl 1:S83-90 - PubMed
  31. Lancet Psychiatry. 2015 Apr;2(4):357-62 - PubMed
  32. Pharmacotherapy. 2006 Oct;26(10):1501-10 - PubMed
  33. Neurology. 2002 Jul 9;59(1):123-5 - PubMed
  34. Epidemiology. 2010 May;21(3):379-82 - PubMed
  35. Pediatrics. 2006 Dec;118(6):2472-80 - PubMed
  36. Nature. 2008 Dec 11;456(7223):702-5 - PubMed
  37. Pharmacol Res. 2010 Sep;62(3):187-206 - PubMed
  38. Anxiety Stress Coping. 2016;29(1):100-17 - PubMed
  39. Science. 1987 May 29;236(4805):1049 - PubMed
  40. J Sports Sci. 2016 Oct;34(20):1965-9 - PubMed
  41. Drugs. 2008;68(13):1803-39 - PubMed
  42. Nature. 2008 Apr 10;452(7188):674-5 - PubMed
  43. Psychopharmacology (Berl). 2002 Jan;159(3):238-47 - PubMed

Publication Types